Loading clinical trials...

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

NCT01393756•The Lymphoma Academic Research Organisation

View on ClinicalTrials.gov

Summary

The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients with follicular lymphoma, (WHO) grade 1, 2 or 3a with at least one of the following signs requiring initiation of treatment:
•* Bulky disease according to the GELF criteria: nodal or extra-nodal mass \>7cm in its greater diameter
•* B symptoms
•* Elevated serum (LDH) or beta 2-microglobulin
•* Involvement of at least 3 nodal sites (each \>3cm)
•* Symptomatic spleen enlargement
•* Compressive syndrome
•* Pleural or peritoneal effusion
•Aged from 18 to 70 years
•WHO performance status 0, 1 or 2
+7 more criteria

Exclusion Criteria

•Previous treatment with immunotherapy or chemotherapy:
•* Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if stopped more than one year before inclusion
•* Rituximab alone during less than three months, if stopped more than one year before inclusion
•Previous radiotherapy except if localized to one lymph node area
•Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative
•Central nervous system or meningeal involvement
•Contraindication to any drug contained in the chemotherapy regimen
•(HIV) disease, active hepatitis B or C
•Any serious active disease or co-morbid medical condition (according to investigator's decision)
•Any of the following laboratory abnormalities.
+13 more criteria

Locations (24)

Institut Bergonié

Bordeaux, France

Polyclinique Bordeaux Nord Aquitaine

Bordeaux, France

CHU Estaing

Clermont-Ferrand, France

Hôpital Henri Mondor

Créteil, France

CHU de DIJON

Dijon, France

Chru Lille

Lille, France

Centre Léon Bérard

Lyon, France

Institut Paoli Calmettes

Marseille, France

Hôpital Notre Dame de Bon Secours

Metz, France

Hôpital Saint Eloi

Montpellier, France

Key Dates

Start Date

December 1, 2010

Primary Completion Date

July 1, 2013

Completion Date

November 1, 2015

Last Updated

December 5, 2023

Enrollment

ACTUAL participants

Conditions

Follicular Lymphoma

Interventions

Lenalidomide and R-CHOP

DRUG

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View study

RECRUITINGPHASE1/PHASE2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

B-cell MalignancyMarginal Zone Lymphoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Inclusion Criteria

Exclusion Criteria

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Odronextamab in Low Tumor Volume Advanced FL

A Long-term Extension Study of PCI-32765 (Ibrutinib)